Molecular characterization of circulating tumor cells in patients with ovarian cancer improves their prognostic significance - A study of the OVCAD consortium

Eva Obermayr*, Dan Cacsire Castillo-Tong, Dietmar Pils, Paul Speiser, Elena Ioana Braicu, Toon Van Gorp, Sven Mahner, Jalid Sehouli, Ignace Vergote, Robert Zeillinger

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

86 Citations (Web of Science)

Abstract

The study aims at identifying novel markers for circulating tumor cells (CTCs) in patients with epithelial ovarian cancer (EOC), and at evaluating their impact on outcome.Microarray analysis comparing matched EOC tissues and peripheral blood leucocytes (N=35) was performed to identify novel CTC markers. Gene expression of these novel markers and of EpCAM was analyzed using RT-qPCR in blood samples taken from healthy females (N=39) and from EOC patients (N=216) before primary treatment and six months after adjuvant chemotherapy. All samples were enriched by density gradient centrifugation. CTC positivity was defined by over-expression of at least one gene as compared to the healthy control group.CTC were detected in 24.5% of the baseline and 20.4% of the follow-up samples, of which two thirds were identified by overexpression of the cyclophilin C gene (PPIC), and just a few by EpCAM overexpression. The presence of CTCs at baseline correlated with the presence of ascites, sub-optimal debulking, and elevated CA-125 and HE-4 levels, whereas CTC during follow-up occurred more often in older and platinum resistant patients. PPIC positive CTCs during follow-up were significantly more often detected in the platinum resistant than in the platinum sensitive patient group, and indicated poor outcome independent from classical prognostic parameters.Molecular characterization of CTC is superior to a mere CTC enumeration or even be the rationale for CTC diagnostics at all. Ultimately CTC diagnostics may lead to more personalized treatment of EOC, especially in the recurrent situation. Published by Elsevier Inc.
Original languageEnglish
Pages (from-to)15-21
JournalGynecologic Oncology
Volume128
Issue number1
DOIs
Publication statusPublished - Jan 2013

Keywords

  • Primary ovarian cancer
  • Circulating tumor cells
  • Molecular marker
  • Platinum resistance
  • Prognostic marker

Cite this